drugset / Trial / NCT04760613

CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)

NCT04760613

RandomizedParallel-groupDouble-blindTreatment

Summary

This double-blind, placebo-controlled, exploratory trial is designed to compare effects of oral CBD 600mg to placebo (PCB) in 20 outpatients with chronic spinal radiculopathies (without co-occurring Opioid Use Disorder), maintained on stable opioid analgesics for a minimum of 1 month. The trial duration will be approximately 2 weeks (from the point of randomization) of daily CBD 600mg vs placebo. Safety and tolerability of CBD will be assessed throughout the trial. The secondary efficacy outcome is change in pain outcomes from baseline to end of the treatment period at 2-weeks post-randomization/initiation of treatment with a Mixed Model for Repeated Measures (MMRM) statistical analysis performed to assess between group treatment effects of CBD relative to placebo.

Timeline

Start
2022-02-03
Primary completion
2023-06-07
Completion
2023-06-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cannabidiol Other / unclassified 600 mg Oral

Indications